杭州奥泰生物技术股份有限公司 2025 年度"提质增效重回报"行动方案 1、深耕主营业务，保持业绩稳步增长 为落实""以投资者为本"的理念，推动杭州奥泰生物技术股份有限公司（以 下简称"公司"）持续优化经营、规范治理和积极回报投资者，大力提高公司质 量，助力信心提振、资本市场稳定和经济高质量发展，公司制定了 2025 年度""提 质增效重回报"行动方案，以进一步提升公司经营效率，强化市场竞争力，保障 投资者权益，树立良好的资本市场形象。主要措施包括： 一、聚焦经营主业，持续创新，提质增效 公司聚焦 POCT（即时检验）细分领域，专业从事体外诊断试剂的全产业链 研发、生产与销售。核心产品线覆盖五大检测领域：毒品及药物滥用检测、传染 病检测、妇女健康检测、肿瘤标志物检测及心脏标志物检测，形成多维度检测解 决方案。产品矩阵涵盖胶体金、荧光免疫、化学发光等多种检测原理，适配专业 医疗机构、基层卫生单位、家庭自测等多场景应用需求。依托自主构建的快速诊 断技术平台，公司持续为临床急诊、公共卫生筛查及个人健康管理领域提供高灵 敏度、强稳定性的创新诊断产品，目前在国内 POCT 领域具有显著的品类优势和 技术竞争力。2024 ...

Core Viewpoint - The company, Aotai Biological Technology Co., Ltd., is experiencing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the context of its strong revenue and profit growth [1][2]. Company Summary - Aotai Biological specializes in the research, production, and sales of in vitro diagnostic reagents, with a diverse product range exceeding 1,200 types, including rapid diagnostic reagents for drug abuse detection, infectious disease testing, women's health, tumor detection, and cardiac markers [1]. - The company has received multiple accolades, including being recognized as one of the top 500 innovative high-tech enterprises in Zhejiang Province and one of the top 50 medical device companies in China for 2022-2023 [1]. Financial Performance - For the third quarter of 2024, the company reported a revenue of 618 million yuan, representing a year-on-year increase of 10.37%, and a net profit of 198 million yuan, reflecting a significant year-on-year growth of 94.48% [2]. - The company's gross profit margin stands at 55.76%, indicating strong profitability [2]. Market Position - As of the latest report, Aotai Biological's rolling PE ratio is 17.26, significantly lower than the industry average of 45.94 and the median of 29.64, positioning the company at 38th in the industry ranking [1][2]. - The total market capitalization of Aotai Biological is 5.24 billion yuan, with 158 institutions holding a total of 8.18 million shares valued at 517 million yuan [1].

证券代码：688606 证券简称：奥泰生物 公告编号：2025-008 杭州奥泰生物技术股份有限公司 关于变更签字注册会计师的公告 1、基本情况 王益宠先生，2015 年成为中国注册会计师，2012 年开始从事上市公司审计， 2015 年开始在致同事务所执业，2024 年开始为公司提供审计服务，近三年签署 上市公司审计报告 12 份。 2、诚信记录 王益宠先生近三年未受到过刑事处罚、行政处罚、行政监管措施和自律处 分，无不良诚信记录。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州奥泰生物技术股份有限公司（以下简称"公司"）分别于 2024 年 4 月 26 日召开第三届董事会第三次会议、2024 年 5 月 30 日召开 2023 年年度股东大 会，审议通过了《关于<公司续聘 2024 年度审计机构>的议案》，同意聘任致同 会计师事务所（特殊普通合伙）（以下简称"致同事务所"）为公司 2024 年度财 务与内部控制审计机构。具体内容详见公司分别于 2024 年 4 月 27 日、2024 年 5 月 31 日在上海 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-006 杭州奥泰生物技术股份有限公司 关于公司全资子公司向全资孙公司增资以实施对 外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）对外投资基本情况 公司专注于体外诊断试剂的生产、研发和销售，为完善公司产业布局，充分 整合利用各方优势资源，推进公司战略规划的实施，巩固并提升公司在行业内的 技术优势地位及核心竞争力，公司拟通过凡天生物以自有资金向凡凌生物增资 1,000 万美元，并通过凡凌生物与杭州临平经济技术开发区管理委员会签订招商 协议书，负责土地招拍挂及厂房建设，投资建设年产 2 亿人份诊断试剂及电子仪 器项目，项目总投资不低于 3 亿元人民币。 （二）对外投资的决策与审批程序 2025 年 3 月 20 日，公司召开第三届董事会第十一次会议及第三届监事会第 十一次会议，审议通过《关于<公司全资子公司向全资孙公司增资以实施对外投 资>的议案》。根据《上海证券交易所科创板股票上市规则》及《杭州奥泰生物技 术股份有限公司章程》的规定，本次对外 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-007 杭州奥泰生物技术股份有限公司 关于使用暂时闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州奥泰生物技术股份有限公司（以下简称"公司"）于 2025 年 3 月 20 日 召开第三届董事会第十一次会议、第三届监事会第十一次会议，审议通过了《关 于<使用暂时闲置自有资金进行现金管理>的议案》，同意公司在确保不影响公司 正常业务开展的情况下,使用最高余额不超过人民币 18 亿元（包含本数）的暂时 闲置自有资金购买安全性高、流动性好的投资产品（包括但不限于协定性存款、 结构性存款、定期存款、通知存款、大额存单等）。在上述额度内,资金可以滚动 使用,使用期限自董事会审议通过之日起 12 个月内有效。 董事会授权公司管理层在授权额度和期限内行使现金管理投资决策权并签署 相关合同文件，具体事项由公司财务部负责组织实施。上述事项在公司董事会审 批权限范围内,无需提交公司股东大会审批。公司监事会发表了明确同意的意见。 现将具体情况公告 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-005 杭州奥泰生物技术股份有限公司 杭州奥泰生物技术股份有限公司（以下简称"公司"）第三届监事会第十一 次会议（以下简称"本次会议"）于 2025 年 3 月 13 日以电子邮件的形式发出会 议通知，于 2025 年 3 月 20 日上午 10：00 在公司会议室以现场与通讯相结合的 方式召开。会议应出席监事 3 名，实际出席监事 3 名。本次会议的召集、召开 程序和方式符合《中华人民共和国公司法》等法律法规以及《杭州奥泰生物技 术股份有限公司章程》的有关规定，会议决议合法、有效。 二、监事会会议审议情况： 会议由监事会主席高跃灿先生主持召开，全体与会监事经认真审议和表决， 形成以下决议 1、审议通过《关于<公司全资子公司向全资孙公司增资以实施对外投资> 的议案》 监事会认为：本次公司全资子公司凡天生物科技有限公司拟以自有资金向 公司全资孙公司凡凌生物科技（杭州）有限责任公司增资 1,000 万美元以实施 对外投资事项符合相关规定，本事项符合公司发展战略，不存在损害公司及股 东利益的情形。 因此，监事会同意公司全资子公司向全资孙公司增资以实施对 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown continuous performance exceeding expectations, with a focus on the POCT (Point of Care Testing) market, demonstrating strong operational improvements and market expansion strategies [1][7] - The company reported a revenue of 870 million yuan for 2024, representing a year-on-year growth of 15.25%, and a net profit attributable to shareholders of 304 million yuan [1][7] - The company aims for a revenue target of 850 million to 1.26 billion yuan from 2024 to 2026, with a compound annual growth rate of 18.6% [1][7] Financial Performance Summary - Total revenue (in million yuan) for 2022A was 3,388.57, with projections of 754.70 for 2023A, 869.79 for 2024E, 1,130.36 for 2025E, and 1,490.89 for 2026E [1][8] - Net profit (in million yuan) for 2022A was 1,184.92, with projections of 180.58 for 2023A, 303.54 for 2024E, 350.62 for 2025E, and 451.17 for 2026E [1][8] - The latest diluted EPS (in yuan/share) is projected to be 3.83 for 2024E, 4.42 for 2025E, and 5.69 for 2026E [1][8] Market Position and Strategy - The company specializes in the research, production, and sales of in vitro diagnostic reagents, with a strong presence in over 160 countries, particularly in Europe and the United States [1][7] - The company has developed 25 new raw materials in 2023, with 4 being domestic firsts, enhancing its competitive edge [1][7] - The company emphasizes internal management and cost control, leading to improved operational efficiency and cash flow [1][7]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has shown continuous performance exceeding expectations, with a focus on the POCT (Point of Care Testing) market, demonstrating strong operational improvements and market expansion strategies [7][8] - The company achieved a total revenue of 870 million yuan in 2024, representing a year-on-year growth of 15.25%, and a net profit attributable to shareholders of 304 million yuan [7] - The company has established a significant international market presence, particularly in Europe and the United States, and has focused on product innovation and cost reduction through self-sufficient raw materials [7][8] Financial Performance Summary - Revenue and Profit Forecasts: - 2024: Revenue of 870 million yuan, net profit of 304 million yuan, and EPS of 3.83 yuan [1][8] - 2025: Revenue projected at 1.13 billion yuan, net profit at 351 million yuan, and EPS at 4.42 yuan [1][8] - 2026: Revenue expected to reach 1.49 billion yuan, net profit at 451 million yuan, and EPS at 5.69 yuan [1][8] - The company has improved its operating cash flow significantly, reaching 192 million yuan in the first three quarters of 2024 [7] - The company aims for a compound annual growth rate (CAGR) of 18.6% in revenue from 2024 to 2026, with a target of 8.5 billion to 12.6 billion yuan in revenue [7][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's 2024 profit exceeded the upper limit of forecasts, with a revenue of 870 million yuan, representing a year-on-year growth of 15.25%, and a net profit attributable to the parent company of 304 million yuan, up 68.18% year-on-year [4][5] - The company has seen a significant increase in customer numbers and has improved its product gross margin through self-production of raw materials and enhanced automation [4][5] - The company has a strategic focus on developing a biological raw material platform, which effectively reduces production costs and enhances product launch efficiency [6] Financial Summary - In 2024, the company is expected to achieve a net profit of 304 million yuan, with projections for 2025 and 2026 at 373 million yuan and 465 million yuan respectively [7] - The earnings per share (EPS) for 2024 is projected to be 3.83 yuan, with corresponding P/E ratios of 17.9, 14.6, and 11.7 for 2024, 2025, and 2026 respectively [4][7] - The company reported a gross margin of 55.7% for 2024, with a net margin of 34.9% [7]

Financial Performance - Total revenue for 2024 reached RMB 86,979.22 million, an increase of 15.25% compared to the previous year[3] - Net profit attributable to shareholders of the parent company was RMB 30,368.83 million, reflecting a growth of 68.18% year-on-year[5] - The profit margin before non-recurring items increased to RMB 23,937.15 million, up 62.92% from the previous year[5] - Basic earnings per share rose to RMB 3.83, a 67.98% increase compared to the same period last year[3] - The weighted average return on equity improved to 7.84%, an increase of 3.32 percentage points[3] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 418,645.82 million, a 1.71% increase from the beginning of the period[4] - Shareholders' equity attributable to the parent company was RMB 388,496.46 million, up 1.51% from the start of the period[4] Operational Focus - The company maintained a strong focus on R&D in the POCT sector, ensuring new product launches every month[6] - The increase in operating profit and total profit was primarily driven by revenue growth and cost control measures[8] - The company emphasizes internal management improvements and production automation to enhance efficiency and quality[6]